Alan M. Garber

CIK: 0001312907

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VRTX

VERTEX PHARMACEUTICALS INC / MA

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

VRTX
VERTEX PHARMACEUTICALS INC / MA
Oct 15, 2026
Award(A)
Deferred Stock Units
Direct
29 shares at avg. $512.44-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Jul 15, 2026
Award(A)
Deferred Stock Units
Direct
32 shares at avg. $475.28-
VRTX
VERTEX PHARMACEUTICALS INC / MA
May 1, 2026
Award(A)
Direct
472 shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Apr 15, 2026
Award(A)
Deferred Stock Units
Direct
34 shares at avg. $442.50-
VRTX
VERTEX PHARMACEUTICALS INC / MA
May 1, 2025
Award(A)
Direct
398 shares-

		Type	Shares	Price		Ownership
Oct 15, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A) Deferred Stock Units	29	$512.44	-	Direct
Jul 15, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A) Deferred Stock Units	32	$475.28	-	Direct
May 1, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A)	472	-	$0	Direct
Apr 15, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A) Deferred Stock Units	34	$442.50	-	Direct
May 1, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A)	398	-	-	Direct

1-5 of 5 transactions

About Garber Alan M

Garber Alan M (SEC CIK 0001312907) files insider reports with the SEC as Director of VERTEX PHARMACEUTICALS INC / MA (VRTX).

Signal8 holds 5 ownership filings by Garber Alan M, all Form 4s, filed between May 5, 2025 and Oct 19, 2026. Those filings report 5 transactions, from May 1, 2025 to Oct 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Garber Alan M's filings is in BOSTON, MA.

Recent filings by Garber Alan M

Oct 15, 2026: Grant or award of VRTX derivative securities (Form 4, code A).
Jul 15, 2026: Grant or award of VRTX derivative securities (Form 4, code A).
May 1, 2026: Grant or award of VRTX shares (Form 4, code A).
Apr 15, 2026: Grant or award of VRTX derivative securities (Form 4, code A).
May 1, 2025: Grant or award of VRTX shares (Form 4, code A).

Other insiders filing for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Brennan Daniel J., Director
SACHS BRUCE I, Director
van Grunsven Jasper, EVP, CP and NPPO
Ambrose Kristen, SVP & Chief Accounting Officer
Tatsis Ourania, EVP, Chief Reg. & Quality Off.
Sachdev Amit, EVP Chief Patient & Ext Af Off

How to read Form 4 transaction codes